Analytical Data
-
Gene name
SMARCC2
- Application
-
Alternative Names
BAF 170; BAF170; BRG1 associated factor 170; BRG1-associated factor 170; Chromatin remodeling complex BAF170 subunit; CRACC 2; CRACC2; Mammalian chromatin remodeling complex BRG1 associated factor 170; Rsc 8; Rsc8; SMARCC 2; Smarcc2; SMRC2_HUMAN; SWI/SNF complex 170 kDa subunit; SWI/SNF complex subunit SMARCC2; SWI/SNF related matrix associated actin dependent regulator of chromatin c2; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily c member 2; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily C member 2; SWI3 like protein
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8TAQ2
-
Expression Region
1-1130 aa
-
AA Sequence
MAVRKKDGGPNVKYYEAADTVTQFDNVRLWLGKNYKKYIQAEPPTNKSLSSLVVQLLQFQEEVFGKHVSNAPLTKLPIKCFLDFKAGGSLCHILAAAYKFKSDQGWRRYDFQNPSRMDRNVEMFMTIEKSLVQNNCLSRPNIFLCPEIEPKLLGKLKDIIKRHQGTVTEDKNNASHVVYPVPGNLEEEEWVRPVMKRDKQVLLHWGYYPDSYDTWIPASEIEASVEDAPTPEKPRKVHAKWILDTDTFNEWMNEEDYEVNDDKNPVSRRKKISAKTLTDEVNSPDSDRRDKKGGNYKKRKRSPSPSPTPEAKKKNAKKGPSTPYTKSKRGHREEEQEDLTKDMDEPSPVPNVEEVTLPKTVNTKKDSESAPVKGGTMTDLDEQEDESMETTGKDEDENSTGNKGEQTKNPDLHEDNVTEQTHHIIIPSYAAWFDYNSVHAIERRALPEFFNGKNKSKTPEIYLAYRNFMIDTYRLNPQEYLTSTACRRNLAGDVCAIMRVHAFLEQWGLINYQVDAESRPTPMGPPPTSHFHVLADTPSGLVPLQPKTPQGRQVDADTKAGRKGKELDDLVPETAKGKPELQTSASQQMLNFPDKGKEKPTDMQNFGLRTDMYTKKNVPSKSKAAASATREWTEQETLLLLEALEMYKDDWNKVSEHVGSRTQDECILHFLRLPIEDPYLEDSEASLGPLAYQPIPFSQSGNPVMSTVAFLASVVDPRVASAAAKSALEEFSKMKEEVPTALVEAHVRKVEEAAKVTGKADPAFGLESSGIAGTTSDEPERIEESGNDEARVEGQATDEKKEPKEPREGGGAIEEEAKEKTSEAPKKDEEKGKEGDSEKESEKSDGDPIVDPEKEKEPKEGQEEVLKEVVESEGERKTKVERDIGEGNLSTAAAAALAAAAVKAKHFAAVEERKIKSLVALLVETQMKKLEIKLRHFEELETIMDREREALEYQRQQLLADRQAFHMEQLKYAEMRARQQHFQQMHQQQQQPPPALPPGSQPIPPTGAAGPPAVHGLAVAPASVVPAPAGSGAPPGSLGPSEQIGQAGSTAGPQQQQPAGAPQPGAVPPGVPPPGPHGPSPFPNQQTPPSMMPGAVPGSGHPGVADPGTPLPPDPTAPSPGTVTPVPPPQ
-
Molecular Weight
149.93 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SMARCC2, a core component of the SWI/SNF chromatin-remodeling complex, plays a crucial role in regulating gene expression and maintaining cellular identity through its involvement in chromatin dynamics. Research has shown that SMARCC2 contributes to various cellular processes, including differentiation, proliferation, and response to environmental signals. Abnormalities in SMARCC2 function are implicated in several diseases, particularly cancer, where dysregulated chromatin remodeling can lead to aberrant gene expression patterns that promote tumorigenesis. Recent studies have focused on the structural and functional characterization of SMARCC2 as a recombinant protein to better understand its mechanisms of action within the chromatin landscape. These investigations aim to elucidate its interactions with other chromatin-associated proteins and provide insights into the complex regulatory networks governing gene expression. By utilizing recombinant protein technology, researchers can produce SMARCC2 in a controlled manner, facilitating biochemical assays and structural analyses. Such studies are expected to unveil potential therapeutic targets and strategies for modulating SMARCC2 activity in disease contexts, offering hope for the development of novel interventions for cancers and other disorders linked to chromatin remodeling dysfunctions. The ongoing research into SMARCC2 and its associated pathways highlights the significance of chromatin dynamics in cellular regulation and underscores the potential of targeting such pathways in therapeutic development.
